Promising Vaccine

Alzheimer's, cardiovascular, and other chronic diseases; biomarkers, lifestyle, supplements, drugs, and health care.
User avatar
LG1
Senior Contributor
Senior Contributor
Posts: 364
Joined: Fri Dec 18, 2015 10:32 am
Location: Dallas, TX

Promising Vaccine

Postby LG1 » Tue Nov 16, 2021 5:26 am

https://www.nature.com/articles/s41380-021-01385-7

In conclusion, we have developed a novel AD vaccine with unique features not related to any other vaccine or antibody in clinical development. The TAPAS family antibodies are uniquely positioned as the antibodies selectively target the early toxic N-terminal truncated species of Aβ found in abundance throughout the brains of AD patients. Moreover, the TAP01 antibody – and its humanised versions – are less likely to become trapped inside plaques thereby increasing the bioavailability after passive immunisation. This decreases the potential for the dose-limiting side effects that have so far proved problematic in clinical trials of other Aβ antibodies.


This looks exciting, promising. Hopeful!!!
ε4/ε4

NewRon
Senior Contributor
Senior Contributor
Posts: 422
Joined: Fri Nov 07, 2014 3:04 am

Re: Promising Vaccine

Postby NewRon » Tue Nov 16, 2021 3:12 pm

Yes, it does, thanks for highlighting it!

Anyone else with more experience than me of reading these studies care to weigh in on it?
Apo E4/E4, Male, Age 56

NF52
Support Team
Support Team
Posts: 1849
Joined: Tue Oct 25, 2016 9:41 am
Location: Eastern U.S.

Re: Promising Vaccine

Postby NF52 » Wed Nov 17, 2021 8:58 am

LG1 wrote:This looks exciting, promising. Hopeful!!!
NewRon wrote:Yes, it does, thanks for highlighting it!
Anyone else with more experience than me of reading these studies care to weigh in on it?
I added some more below from the conclusion LG1 cited. Interesting that the researchers see this as a better version of the anti-amyloid drug donanemab, which has started Trailblazer-ALZ-3 a Phase III trial of 3300 cognitively unimpaired people with amyloid beta and "early tau" on PET scans. The researchers here seem to predict that their antibody will not cause the ARIA-E (Amyloid-related imaging abnormalities-brain edema) that occurs in about 25% of the donanemab trial participants.

Sounds like they are seeking vaccine companies to aid in development and funding from either the EU or US for early Phase 1 safety trials. It's a promise that may be 10 years off, given the time needed for careful human studies. I hope they'll be invited to present more at the 2022 Alzheimer's Association conference.

The novel TAPAS family of antibodies have revealed two new attractive options for therapeutic intervention in AD... The lead therapeutic antibody for clinical assessment is TAP01_04, which is a humanised variant of TAP01 retaining the high specificity and affinity of the mouse parent antibody ...For a trail blazing vaccine-based approach to AD, formulation of the candidate cyclised Aβ peptides is likely to be a key factor to ensure a strong immune response and will require expertise from specialist vaccine development organisations. The design of the TRAILBLAZER-ALZ phase II registration quality trial to evaluate safety, tolerability and efficacy of donanemab will be helpful to design clinical trials targeting the TAPAS epitope. As donanemab completely cleared plaques in two-thirds of participants and slowed cognitive decline in some patients, the pathological status appears crucial for a successful treatment strategy.
4/4 and still an optimist!

User avatar
LG1
Senior Contributor
Senior Contributor
Posts: 364
Joined: Fri Dec 18, 2015 10:32 am
Location: Dallas, TX

Re: Promising Vaccine

Postby LG1 » Wed Nov 17, 2021 6:41 pm

Thanks for expanding on it and yes, it would be a fantastic addition to the conference!
ε4/ε4

Mitrofan
Contributor
Contributor
Posts: 4
Joined: Thu Feb 06, 2020 5:34 am

Re: Promising Vaccine

Postby Mitrofan » Thu Nov 25, 2021 8:34 am

Alzheimer's nasal vaccine to enter human trials for the first time

The first human clinical trial of a nasal vaccine to slow the progression of Alzheimer's disease is set to begin after nearly 20 years of research.

This is a "remarkable milestone," according to Dr. Howard Weiner, co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital in Boston.

"Over the last two decades, we've amassed preclinical evidence suggesting the potential of this nasal vaccine for AD [Alzheimer's disease]," Weiner said in a hospital news release. "If clinical trials in humans show that the vaccine is safe and effective, this could represent a nontoxic treatment for people with Alzheimer's, and it could also be given early to help prevent Alzheimer's in people at risk."


https://www.webmd.com/alzheimers/news/2 ... rs-disease


Return to “Prevention and Treatment”

Who is online

Users browsing this forum: No registered users and 7 guests